Communiqués Ironwood Pharmaceuticals, Inc.

Actions

IRWD

US46333X1081

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 23/07/2026			Varia. 5j.	Varia. 1 janv.
3,790 ^USD	-2,32%		-2,07%	+12,46%

14/07	Ironwood Pharmaceuticals, Inc. annonce des changements au sein de sa direction	CI
27/05	Ironwood annonce le feu vert de la FDA pour l'utilisation du Linzess chez les enfants de deux ans et plus souffrant de constipation fonctionnelle	MT

Communiqués

15/07	Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development, STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients	AQ
14/07	Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients	BU
28/05	Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference	BU
27/05	FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)	BU
08/05	Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth, Maintains Full-Year 2026 Financial Guidance	AQ
08/05	Ironwood Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Ironwood Pharmaceuticals : Q1 2026 Update	PU
07/05	Ironwood: Q1 Earnings Snapshot	AQ
07/05	Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance	BU
04/05	Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)	BU
30/04	Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call	BU
23/04	Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026	BU
04/03	Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference	BU
25/02	Ironwood: Q4 Earnings Snapshot	AQ
25/02	Ironwood Pharmaceuticals : Fourth Quarter 2025 Ironwood 4Q 2025 Investor Update	PU
25/02	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook	BU
18/02	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call	BU
02/01	Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance	BU
13/11	Ironwood Pharmaceuticals : Third Quarter 2025 Ironwood 3Q 2025 Update	PU
10/11	Ironwood: Q3 Earnings Snapshot	AQ
10/11	Ironwood Pharmaceuticals : Q3 2025 Update	PU
10/11	Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance	BU
07/08/25	Ironwood: Q2 Earnings Snapshot	AQ
07/08/25	Ironwood Pharmaceuticals : Second Quarter 2025 Ironwood 2Q 2025 Update	PU
07/08/25	Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance	BU